A drug labelled GC376 owned by a company called Anivive has already been lab tested in Canada in 2020 in 2 months and promoted for Covid-19 clinical trials and human use partly on the basis it was shown some years ago as effective against a 100% fatal cat coronavirus FIP and tested on cats. It is not currently approved to treat cats with FIP
However Anivive's GC376 was only 35% effective in Uni of California trials on cats with the 100% fatal coronavirus infection FIP
Gileads GS-441524 was 100% effective in curing cats of FIP during Uni of California trials
Both trials were carried out at the Uni of California some years ago by Professor Pedersen
Below are the peer reviewed published studies on GS-441524 and GC376
www.sciencedirect.com
journals.sagepub.com
Gilead Conflict ???
Gilead owns both remdesivir (GS-5734) its Covid-19 treatment and the drug GS-441524 which was also successful against SARS and MERS
GS-441524 is the main metabolite of Remdesivir - effectively the main anti Covid-19 compound
Gilead has blocked all use of GS-441524 on animals or people.
Someone needs to look into this as even the FDA has admitted in writing that long standing research on GS-441524 shows lots of merit for a potentional Covid-19 treatment.
Gilead and the FDA need to answer questions on what is going on particularly as Uni of Texas researchers have indicated that GS-441524 could be more effective than remdesivir against Covid-19 and cheaper and easier to produce.
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
Victoria C. Yan* and Florian L. Muller
Cite this: ACS Med. Chem. Lett. 2020, 11, 7, 1361–1366
Publication Date:June 23, 2020
Cat FIP Coronavirus Research summary
Prof Pedersen Uni of California
Antiviral GC376 out of Kansas State University had previously been tested but only seven out of 20 cats had gone into remission. Those results seemed impressive at the time, but Gileads GS-441524 appeared to be even better
Pedersen then infected 10 cats with FIP and dosed them with GS-441524. All 10 cats recovered.
“We almost fell out of our chairs,” says Weigner.
in a follow-up field trial of 31 pets with naturally acquired FIP, 25 ultimately made it—an unheard-of recovery rate.
Despite the success, Gilead refused to license GS-441524 for use in cats. However cat owners and charities obtain GS-441524 from the unofficial market as it is easy to make and normally 100% effective against the 100% fatal cat coronavirus FIP
www.theatlantic.com
GC376 FIP cat study Uni of California Prof Pedersen - 35% recovery rate
"Relapses no longer responsive to treatment occurred in 13 of these 19 cats within 1-7 weeks of initial or repeat treatment(s). Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions. At the time of writing, seven cats were in disease remission."
GS-441524 FIP cat study by Uni of California Professor Pedersen - 100% recovery rate
"All ten of the ........treated cats have remained normal to date (more than eight months post infection). No significant signs of toxicity were noted during or after primary or secondary treatment."
Below is the recent Uni of Alberta / Canada study on drug GC376 citing its effectiveness against the fatal cat coronavirus FIP as part of the basis for the research as a covid-19 treatment but not stating the 35% remission rate compared to 100% rate for GS-441524
The owner of patent for GC376 is Anivive who is happy for clinical trials to go ahead for both treatment for Cats FIP and Covid-19 while Gilead blocks co-operation, research and production
Joanne Lemieux, a professor of biochemistry in the Faculty of Medicine & Dentistry at the University of Alberta said
“This drug (GC376) is very likely to work in humans, so we’re encouraged that it will be an effective antiviral treatment for COVID-19 patients.”
she said the current drug shows enough antiviral action against SARS-CoV-2 to proceed immediately to clinical trials.
“Typically for a drug to go into clinical trials, it has to be confirmed in the lab and then tested in animal models,” Lemieux said. “Because this drug has already been used to treat cats with coronavirus, and it's effective with little to no toxicity, it's already passed those stages and this allows us to move forward.”
“Because of the strong data that we and others have gathered we’re pursuing clinical trials for this drug as an antiviral for COVID-19.”
The researchers have established a collaboration with Anivive Life Sciences, a veterinary medicine company that is developing the drug for cats, to produce the quality and quantity of drug needed for human clinical trials.
Lemieux said it will likely be tested in Alberta in combination with other promising antivirals such as remdesivir, the first treatment approved for conditional use in some countries including the United States and Canada.
“In just two months, our results have shown that the drug is effective at inhibiting viral replication in cells with SARS-CoV-2,” said Joanne Lemieux, a professor of biochemistry in the Faculty of Medicine & Dentistry.
www6.slac.stanford.edu
Anivive Repurposes Veterinary Drug GC376 for COVID-19 And Submits Pre-IND to FDA - 26th May 2020
The article below is good but fails to disclose how Gilead has withheld GS-441524 for some years from animal use or any research despite amazing clinical trial results and repeated requests to license and produce the drug. GS-441524 remains in widespread unofficial use as a very successful life saving drug and only treatment for FIP that is almost 100% effective.
Gilead's conduct on GS-441524 seems highly suspect and certainly very inhumane
www.sciencenews.org
However Anivive's GC376 was only 35% effective in Uni of California trials on cats with the 100% fatal coronavirus infection FIP
Gileads GS-441524 was 100% effective in curing cats of FIP during Uni of California trials
Both trials were carried out at the Uni of California some years ago by Professor Pedersen
Below are the peer reviewed published studies on GS-441524 and GC376
The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies
Feline infectious peritonitis (FIP) is a common and highly lethal coronavirus disease of domestic cats. Recent studies of diseases caused by several R…
SAGE Journals: Your gateway to world-class research journals
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.
journals.sagepub.com
Gilead Conflict ???
Gilead owns both remdesivir (GS-5734) its Covid-19 treatment and the drug GS-441524 which was also successful against SARS and MERS
GS-441524 is the main metabolite of Remdesivir - effectively the main anti Covid-19 compound
Gilead has blocked all use of GS-441524 on animals or people.
Someone needs to look into this as even the FDA has admitted in writing that long standing research on GS-441524 shows lots of merit for a potentional Covid-19 treatment.
Gilead and the FDA need to answer questions on what is going on particularly as Uni of Texas researchers have indicated that GS-441524 could be more effective than remdesivir against Covid-19 and cheaper and easier to produce.
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
Victoria C. Yan* and Florian L. Muller
Cite this: ACS Med. Chem. Lett. 2020, 11, 7, 1361–1366
Publication Date:June 23, 2020
Cat FIP Coronavirus Research summary
Prof Pedersen Uni of California
Antiviral GC376 out of Kansas State University had previously been tested but only seven out of 20 cats had gone into remission. Those results seemed impressive at the time, but Gileads GS-441524 appeared to be even better
Pedersen then infected 10 cats with FIP and dosed them with GS-441524. All 10 cats recovered.
“We almost fell out of our chairs,” says Weigner.
in a follow-up field trial of 31 pets with naturally acquired FIP, 25 ultimately made it—an unheard-of recovery rate.
Despite the success, Gilead refused to license GS-441524 for use in cats. However cat owners and charities obtain GS-441524 from the unofficial market as it is easy to make and normally 100% effective against the 100% fatal cat coronavirus FIP
A Much-Hyped COVID-19 Drug Is Almost Identical to a Black-Market Cat Cure
Cat owners are resorting to China’s underground marketplace to buy antivirals for a feline coronavirus.
GC376 FIP cat study Uni of California Prof Pedersen - 35% recovery rate
"Relapses no longer responsive to treatment occurred in 13 of these 19 cats within 1-7 weeks of initial or repeat treatment(s). Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions. At the time of writing, seven cats were in disease remission."
GS-441524 FIP cat study by Uni of California Professor Pedersen - 100% recovery rate
"All ten of the ........treated cats have remained normal to date (more than eight months post infection). No significant signs of toxicity were noted during or after primary or secondary treatment."
Below is the recent Uni of Alberta / Canada study on drug GC376 citing its effectiveness against the fatal cat coronavirus FIP as part of the basis for the research as a covid-19 treatment but not stating the 35% remission rate compared to 100% rate for GS-441524
The owner of patent for GC376 is Anivive who is happy for clinical trials to go ahead for both treatment for Cats FIP and Covid-19 while Gilead blocks co-operation, research and production
Joanne Lemieux, a professor of biochemistry in the Faculty of Medicine & Dentistry at the University of Alberta said
“This drug (GC376) is very likely to work in humans, so we’re encouraged that it will be an effective antiviral treatment for COVID-19 patients.”
she said the current drug shows enough antiviral action against SARS-CoV-2 to proceed immediately to clinical trials.
“Typically for a drug to go into clinical trials, it has to be confirmed in the lab and then tested in animal models,” Lemieux said. “Because this drug has already been used to treat cats with coronavirus, and it's effective with little to no toxicity, it's already passed those stages and this allows us to move forward.”
“Because of the strong data that we and others have gathered we’re pursuing clinical trials for this drug as an antiviral for COVID-19.”
The researchers have established a collaboration with Anivive Life Sciences, a veterinary medicine company that is developing the drug for cats, to produce the quality and quantity of drug needed for human clinical trials.
Lemieux said it will likely be tested in Alberta in combination with other promising antivirals such as remdesivir, the first treatment approved for conditional use in some countries including the United States and Canada.
“In just two months, our results have shown that the drug is effective at inhibiting viral replication in cells with SARS-CoV-2,” said Joanne Lemieux, a professor of biochemistry in the Faculty of Medicine & Dentistry.
In a search for COVID-19 treatments, researchers pursue a drug used on cats | SLAC National Accelerator Laboratory
University of Alberta researchers worked with SLAC X-ray scientists to explore the potential of a feline coronavirus drug that may be effective against SARS-CoV-2.
www6.slac.stanford.edu
Anivive Repurposes Veterinary Drug GC376 for COVID-19 And Submits Pre-IND to FDA - 26th May 2020
The article below is good but fails to disclose how Gilead has withheld GS-441524 for some years from animal use or any research despite amazing clinical trial results and repeated requests to license and produce the drug. GS-441524 remains in widespread unofficial use as a very successful life saving drug and only treatment for FIP that is almost 100% effective.
Gilead's conduct on GS-441524 seems highly suspect and certainly very inhumane
How two coronavirus drugs for cats might help humans fight COVID-19
Scientists are exploring if drugs for a disease caused by a coronavirus that infects only cats might help also people infected with the coronavirus.
www.sciencenews.org
Last edited:
Facebook
Twitter
Instagram